Skip to main content

Table 4 Demographic and clinical characteristics of the patients who maintained clinical remission or experienced a relapse of UC with IFX scheduled-maintenance treatment

From: Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience

Characteristics Clinical remission with IFX maintenance (n = 7) Relapse requiring IFX intensification (n = 17) p value
Sex (men/women), n (%) 5 (71.4)/2 (28.6) 11 (64.7)/6 (35.3) 0.64
Age (years)* 38.6 ± 20.7 43.1 ± 15.2 0.64
Disease duration (years)* 7.2 ± 3.5 6.8 ± 4.3 0.68
Modified Truelove and Witts severity index* 7.9 ± 3.6 10.3 ± 3.0 0.23
Mayo score (endoscopy)* 3.0 ± 0.0 2.7 ± 0.5 0.02
Extent of disease    
  Left-side type, n (%) 2 (28.6) 10 (58.8) 0.17
  Extensive colitis, n (%) 5 (71.4) 7 (41.2)
Concomitant medications    
  Corticoteroids, n (%) 0 (0.0) 7 (41.2) 0.04
  Azathioprine/Mercaptopurine, n (%) 4 (57.1) 9 (52.9) 0.85
  Tacrolimus, n (%) 3 (42.9) 5 (29.4) 0.53
Hemoglobin >9.8 g/dl at IFX initiation, n (%) 5 (71.4) 10 (58.8) 0.56
Serum albumin >35 g/L at IFX initiation, n (%) 2 (28.6) 10 (58.8) 0.18
Serum CRP <5 mg/L at 2 weeks after IFX initiation, n (%) 6 (85.7) 12 (70.6) 0.44
  1. IFX: infliximab, CR: clinical remission, CRP: C-reactive protein.
  2. Result reported as number (%) of patients or *mean ± standard deviation.